Profound Medical to Showcase Innovations at a Major Conference
Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) recently made headlines by announcing its participation in an important investment conference. This notable event, the Lake Street Capital Markets "BIG9" conference, is set to take place in the vibrant atmosphere of New York City.
Event Highlights and Schedule
On the scheduled day, management from Profound will engage in one-on-one meetings with investors, sharing insights into the company's cutting-edge medical technology developments. Due to the nature of the event, there won’t be a webcast, but the interactions promise to be enriching for all stakeholders involved.
Introducing Profound Medical Corp.
Profound Medical is not just another entry into the healthcare sector. It’s a commercial-stage company proudly offering customizable, incision-free therapies aimed at abating diseased tissue. Their commitment to innovation sets them apart in the ever-evolving medical device landscape.
The TULSA-PRO Technology
At the forefront of Profound’s offerings is TULSA-PRO, a remarkable technology that amalgamates real-time MRI, AI-enhanced planning, and advanced ultrasound techniques. This unique combination allows for precise control of temperature to effectively target and treat prostate tissue. The TULSA procedure is gaining traction as a mainstream treatment for various prostate conditions, including prostate cancer and benign prostatic hyperplasia (BPH). It's designed to be a one-and-done procedure that minimizes recovery time, with patients often resuming their daily activities shortly after.
Broadening Horizons with Sonalleve
In addition to TULSA-PRO, Profound is poised to grow its market share with Sonalleve, an innovative platform that targets uterine fibroids and alleviates pain caused by bone metastases. This platform has received CE marking and regulatory approval in various regions, including robust support from the China National Medical Products Administration. It also holds FDA approval under a Humanitarian Device Exemption.
Future Prospects and Innovations
The potential for Sonalleve extends beyond its current applications, as Profound investigates new treatment markets where this advanced technology could prove beneficial—such as cancer therapy involving non-invasive ablation of abdominal tumors. As research continues, the outlook for these technologies remains promising.
Connecting with Investors
The upcoming conference provides Profound Medical the opportunity to strengthen its connections with investors and highlight the advancements made in their therapies. As interest in minimally invasive medical treatments rises, the company stands ready to lead the charge into new possibilities.
Contact Information for Inquiries
For further engagement and inquiries, interested parties can reach out to Stephen Kilmer, the Investor Relations contact at Profound Medical Corp., via email at skilmer@profoundmedical.com or call 647.872.4849. Stephen is prepared to provide deeper insights into the company’s innovative projects and future plans.
Frequently Asked Questions
What is the focus of Profound Medical Corp.?
Profound Medical focuses on developing customizable, incision-free therapies for treating diseased tissue, with a primary emphasis on prostate and uterine conditions.
Where is the Lake Street Capital Markets conference held?
The conference takes place in New York City, providing a hub for investors and companies to connect and explore potential collaborations.
What are the main technologies offered by Profound Medical?
Profound offers TULSA-PRO, targeting prostate ailments, and Sonalleve, aimed at treating uterine fibroids and managing pain from bone metastases.
Is TULSA a safe treatment option?
Yes, TULSA is designed to be a safe and effective one-session procedure, minimizing recovery time and associated risks typically related to surgery.
How can investors learn more about Profound Medical?
Investors can gain insights by participating in events like the Lake Street Capital Markets conference or by contacting the Investor Relations department for more information.
